Pharmacokinetic and pharmacodynamic properties of orally administered torsemide in healthy horses

Journal of Veterinary Internal Medicine
Gustavo F AgneRamiro Toribio

Abstract

Diuretic treatment is the mainstay for management of congestive heart failure in horses, and its use has been restricted to injectable medications because no currently data supports the use of PO administered loop diuretics. To determine the pharmacokinetic and pharmacodynamic properties of PO administered torsemide and, determine if PO administered torsemide, could be used as an alternative to injectable diuretics in the horse. Six healthy adult mares. A 2-phase, prospective study, that consisted of pharmacokinetic profiling of a single dose (6 mg/kg PO) and pharmacodynamic effects of long-term torsemide administration (2 mg/kg PO q12h) for 6 days in healthy horses. Pharmacokinetic analysis identified a peak concentration (Cmax ) of 10.14 µg/mL (range, 6.79-14.69 µg/mL) and elimination half-life (T1/2 ) 9.2 hours (range, 8.4-10.4 hours). The area under the plasma drug concentration over time curve (AUC) was 80.7 µg × h/mL (range, 56.5-117.2 µg × h/mL). A statistically significant increase in urine volume and decrease in urine specific gravity were found from day 0 (baseline) to day 6 (P < .0001). Significant alterations in biochemical variables included hyponatremia, hypokalemia, hypochloremia, and increased serum creatinine c...Continue Reading

References

Nov 26, 1991·European Journal of Pharmacology·T UchidaM Watanabe
Jan 1, 1990·European Journal of Clinical Pharmacology·H SpahnE Mutschler
Jan 1, 1986·European Journal of Clinical Pharmacology·J BroekhuysenA Herchuelz
Nov 1, 1982·General and Comparative Endocrinology·G P GuthrieT A Kotchen
Jun 1, 1980·Clinical Pharmacology and Therapeutics·B Odlind, B Beermann
Sep 1, 1995·Equine Veterinary Journal. Supplement·J D Baggot
Feb 25, 1998·Clinical Pharmacokinetics·H Knauf, E Mutschler
Aug 6, 1998·The New England Journal of Medicine·D C Brater
Aug 11, 1998·Life Sciences·T L GoodfriendV Bähr
Jun 29, 2000·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·L DubourgJ P Guignard
Jul 1, 1995·American Journal of Therapeutics·William G. Kramer
Nov 6, 2003·The Journal of Veterinary Medical Science·Masami UechiYumi Ishikawa
Jun 19, 2007·The Veterinary Record·A Caro-VadilloJ A Montoya-Alonso
Oct 6, 2007·American Journal of Veterinary Research·Yasutomo HoriSei-ichi Higuchi
Jul 3, 2009·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Hiroko TanakaYoshifusa Aizawa
May 27, 2011·Equine Veterinary Journal. Supplement·A JanssonC Kvart
Mar 1, 2012·Journal of Veterinary Cardiology : the Official Journal of the European Society of Veterinary Cardiology·Gordon D PeddleMark A Oyama
Jan 18, 2013·Journal of Veterinary Internal Medicine·E McConachieS Giguère
Feb 13, 2013·Journal of Veterinary Internal Medicine·K A DembekR E Toribio
Aug 21, 2013·Journal of Veterinary Internal Medicine·T AfonsoA E Coleman
Mar 15, 2015·The Veterinary Clinics of North America. Equine Practice·Stacey Sullivan, Kenneth Hinchcliff
Nov 3, 2016·Journal of Veterinary Pharmacology and Therapeutics·A PaulinF Woehrlé
Mar 23, 2017·The Veterinary Clinics of North America. Equine Practice·Meg M Sleeper

❮ Previous
Next ❯

Methods Mentioned

BETA
blood collection
urine collection

Software Mentioned

GraphPad Prism
Phoenix WinNonlin

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.